You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表现》和铂医药-B(02142.HK)暗盘高开17%报14.5元
阿思达克 12-09 16:16
根据辉立交易平台显示,明天挂牌的和铂医药-B(02142.HK)暗盘高开17%报14.5元获承接,最高见16元,现造15元,较上市价12.38元,高21%,成交78万股。

和铂是一家仍处於临床阶段的生物制药公司,主要从事研发免疫与肿瘤疾病领域的差异化抗体疗法。是次在港上市共发售约1.38亿股,并已引入Black Rock Funds、HBM Health、高瓴资本、Hudson Bay Capital、Octagon及安澜资本等9个基石投资者,合共认购5,761.2万股;其中10%公开发售获77.5倍超购,已启动回拨机制占比增至40%,认购一手中签率仅10%;股份以略高於招股范围(11.7-12.92元)中间位定价,料集资净额约15.99亿元,主要用作研发核心产品HBM9161与及HBM9036、开发支柱资产HBM4003、注册备案和潜在商业化、用於其他候选药物研发、和铂抗体平台产生创新型分子发现及合作项目等。上市联席保荐人分别为大摩、美国银行及中信证券。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account